DCLK3

Across TCGA pan-cancer cohorts, DCLK3 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of DCLK3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where DCLK3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types DCLK3 is over-expressed in tumor.

KIRC, STAD, and HNSC are the cancer types where DCLK3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DCLK3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	IV	+0.616	<.001	12	view →
STAD	Male	IV	+0.525	<.001	10	view →
HNSC	Female	All	+0.432	<.001	10	view →
COAD	Male	II,III,IV	+0.320	<.001	10	view →
LIHC	Female	II,III,IV	+0.178	<.001	8	view →
BRCA	Female	II,III,IV	+0.125	.010	8	view →
THCA	Female	All	+0.292	<.001	7	view →
LUAD	Male	All	+0.223	<.001	5	view →
CHOL	All	All	+0.216	.005	4	view →
LUSC	All	II,III,IV	+0.209	.003	4	view →
KICH	All	All	+0.148	.004	4	view →
READ	Male	All	+1.350	.013	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

DCLK3–KIRC

Open the KIRC breakdown →